The DOI matches its Crossref record; 131 of the 135 references it cites were found in a registry or an index, and 1 are not checked yet.
Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death
Open accessAbstract
Named as the guardian of the genome, p53 is a tumor suppressor that regulates cell function, often through many different mechanisms such as DNA repair, apoptosis, cell cycle arrest, senescence, metabolism, and autophagy. One of the genes that p53 activates is MDM2, which forms a negative feedback loop since MDM2 induces the degradation of p53. When p53 activity is inhibited, damaged cells do not undergo cell cycle arrest or apoptosis. As 50% of human cancers inactivate p53 by mutation, current research focuses on reactivating p53 by developing drugs that target the p53-MDM2 interaction, which includes the binding of MDM2 and phosphorylation of p53. The objective of this article is to provide a short list and description of p53-MDM2 antagonists that may be excellent candidates for inducing cancer cell death. Relevant articles were searched for and identified using online databases such as PubMed and ScienceDirect. Increasing p53 levels, by targeting the p53-MDM2 interaction, can help p53 play its role as a tumor suppressor and induce cancer cell death. Researchers have identified different compounds that can act as inhibitors, either by directly binding to MDM2 or by modifying p53 with phosphorylation. The results associated with the drugs demonstrate the importance of targeting such interactions to inhibit cancer cell growth, which indicates that the use of the compounds may improve cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although a limitation is the differing subcutaneous tumor microenvironment, there is strong evidence that the cytotoxicity of MDM2 inhibitors is largely tumor cell autonomous (39, 40).”
From Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma (2025) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Panche, A. N., Diwan, A. D., & Chandra, S. R. (2016) · Journal of Nutritional Science · doi:10.1017/jns.2016.41 · Cited by 5,298
Chemistry and Biological Activities of Flavonoids: An Overview
Kumar, S., & Pandey, A. K. (2013) · The Scientific World Journal · doi:10.1155/2013/162750 · Cited by 4,980
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Live or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
Enhanced Phosphorylation of p53 by ATM in Response to DNA Damage
Banin, S., Moyal, L., Shieh, S.-Y., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y., et al. (1998) · Science · doi:10.1126/science.281.5383.1674 · Cited by 1,797
Concepts in sumoylation: a decade on
Geiss-Friedlander, R., & Melchior, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2293 · Cited by 1,785
γH2AX: a sensitive molecular marker of DNA damage and repair
Mah, L.-J., El-Osta, A., & Karagiannis, T. C. (2010) · Leukemia · doi:10.1038/leu.2010.6 · Cited by 1,557
Cited by
Qin, R., You, F.-M., Zhao, Q., Xie, X., Peng, C., Zhan, G., & Han, B. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01350-z · Cited by 131
p53/MDM2 signaling pathway in aging, senescence and tumorigenesis
Huang, Y., Che, X., Wang, P. W., & Qu, X. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.05.001 · Cited by 94
The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer
Wallis, B., Bowman, K. E. R., Lu, P., & Lim, C. S. (2023) · Biomolecules · doi:10.3390/biom13010159 · Cited by 63
Vicente, A. T. S., & Salvador, J. A. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911068 · Cited by 56
De novo molecular design with deep molecular generative models for PPI inhibitors
Wang, J., Chu, Y., Mao, J., Jeon, H.-N., Jin, H., Zeb, A., Jang, Y., Cho, K., Song, T., & No, K. T. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac285 · Cited by 58
Chahat, Bhatia, R., & Kumar, B. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115020 · Cited by 40
TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress
Zhu, K., Su, F., Yang, J., Xiao, R., Wu, R.-Y., Cao, M.-Y., Ling, X., & Zhang, T. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09097-7 · Cited by 40
p53 and Myofibroblast Apoptosis in Organ Fibrosis
McElhinney, K., Irnaten, M., & O'Brien, C. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076737 · Cited by 39
An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53
Huang, Y., Jiao, Z., Fu, Y., Hou, Y., Sun, J., Hu, F., Yu, S., Gong, K., Liu, Y., & Zhao, G. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116121 · Cited by 34
Sánchez-Sandoval, A. L., Hernández‐Plata, E., & Gómora, J. C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1206136 · Cited by 35
C3-Spirooxindoles: Divergent chemical synthesis and bioactivities (2018–2023)
Helal, M. H., Owda, M. E., Mogharbel, A. T., Alessa, A. H., Omer, N., Abdelaziz, M. A., Ibrahim, I., & Eliwa, E. M. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107091 · Cited by 31
MDM2 inhibition in the treatment of glioblastoma: From concept to clinical investigation
Pellot Ortiz, K. I., Rechberger, J. S., Nonnenbroich, L. F., Daniels, D. J., & Sarkaria, J. N. (2023) · Biomedicines · doi:10.3390/biomedicines11071879 · Cited by 30
Functions and mechanisms of non-histone post-translational modifications in cancer progression
Li, Z., Zhu, T., Wu, Y., Yu, Y., Zang, Y.-J., Yu, L., & Zhang, Z. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02410-2 · Cited by 32
Traditional Chinese medicine in the treatment of breast Cancer
Song, P., Liu, T., Zhang, Y., Shao, T., Li, R., Chen, A., Cao, L.-Q., Chen, Z., Guo, W., & Duan, D. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02416-5 · Cited by 29
Explore drug-like space with deep generative models
Wang, J., Mao, J., Wang, M., Le, X., & Wang, Y. (2023) · Methods · doi:10.1016/j.ymeth.2023.01.004 · Cited by 32
Feng, K., Liu, J., Gong, L., Ye, T., Chen, Z., Wang, Y., Li, Q., & Xie, X. (2025) · Advanced Science · doi:10.1002/advs.202413759 · Cited by 38
Recent advances in developing targeted protein degraders
Cheng, B., Li, H., Peng, X., Chen, J., Shao, C., & Kong, Z. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117212 · Cited by 31
Ubiquitination in cancer: mechanisms and therapeutic opportunities
Zhu, S., Zhang, X., Liu, W., Zhou, Z. G., Xiong, S., Li, J., Chen, X., & Peng, C. (2025) · 癌症:英文版 · doi:10.1002/cac2.70044 · Cited by 27
Emerging role and therapeutic implications of p53 in intervertebral disc degeneration
Wang, Y., Hu, S., Zhang, W., Zhang, B.-F., & Yang, Z. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01730-5 · Cited by 22
The ubiquitin-proteasome system in the regulation of tumor dormancy and recurrence
Alhasan, B. A., Morozov, A. V., Guzhova, I. V., & Margulis, B. A. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189119 · Cited by 23
LLM Based Biological Named Entity Recognition from Scientific Literature
Jung, S. J., Kim, H., & Jang, K. S. (2024) · 2024 IEEE International Conference on Big Data and Smart Computing (BigComp) · doi:10.1109/bigcomp60711.2024.00095 · Cited by 19
Chowdhary, S., Preeti, P., Shekhar, S., Gupta, N., Kumar, R., & Kumar, V. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2436908 · Cited by 19
Xu, B., Maimaitijiang, A., Nuerbiyamu, D., Su, Z., & Li, W. (2025) · Biomolecules · doi:10.3390/biom15081088 · Cited by 23
Liu, W., Ma, Y., He, Y., Liu, Y., Guo, Z., He, J., Han, X., Hu, Y., Li, M., Jiang, R., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00784 · Cited by 20
da Silva, J. L., Oliveira, L. J. D. C., de Resende, C. A. A., Reinert, T., de Albuquerque, L. Z., Leite, L. F., & Mano, M. S. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251353623 · Cited by 21
Wang, K., Jiang, M., Liu, H., Meng, C., Li, M., & Lu, H. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107319 · Cited by 17
Novel Anti-Cancer Stem Cell Compounds: A Comprehensive Review
Guo, S., Zheng, S., Liu, M., & Wang, G. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081024 · Cited by 18
The E3 Ligases in Cervical Cancer and Endometrial Cancer
Zhai, F., Wang, J., Yang, W., Ye, M., & Jin, X. (2022) · Cancers · doi:10.3390/cancers14215354 · Cited by 17
Extrachromosomal circular DNA and their roles in cancer progression
Zheng, S., Li, Y., Wang, L., Wei, Q., Wei, M., Yu, T., & Zhao, L. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101202 · Cited by 16
MDMX in Cancer: A Partner of p53 and a p53-Independent Effector
Wu, L., Yan, Y., Huang, Q., & Zheng, D. (2024) · Biologics · doi:10.2147/btt.s436629 · Cited by 21
PROteolysis‐Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives
Vicente, A. T. S., & Salvador, J. A. R. (2024) · MedComm · doi:10.1002/mco2.575 · Cited by 14
Chen, X., Tian, B., Wang, Y., Zheng, J., & Kang, X. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5533 · Cited by 17
Ma, X., Gan, Y., Mai, Z., Song, Y., Zhang, M., & Xia, W. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096284068240506095417 · Cited by 14
Yang, W., Wang, J., Zhao, L., & Chen, J. (2024) · Molecules · doi:10.3390/molecules29143377 · Cited by 15
Development of natural product-based targeted protein degraders as anticancer agents
Chen, C., Feng, Y., Zhou, C., Liu, Z., Tang, Z., Zhang, Y., Li, T., Gu, C., & Chen, J. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107772 · Cited by 14
Chaperone-mediated autophagy as a modulator of aging and longevity
Endicott, S. J. (2024) · Frontiers in Aging · doi:10.3389/fragi.2024.1509400 · Cited by 19
Molecularly Targeted Therapies in Oncology: Mechanisms, Resistance, and Combination Strategies
Giercuszkiewicz-Haśnik, K., MORAK-MŁODAWSKA, B. I., & Jeleń, M. (2026) · Molecules · doi:10.3390/molecules31071195 · Cited by 15
Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53
Liu, Z., Yang, Y., Sun, X., Ma, R., Zhang, W., Wang, W., Yang, G., Wang, H., Zhang, J., Wang, Y., et al. (2024) · Molecules · doi:10.3390/molecules29030725 · Cited by 12
Decoding the molecular symphony: interactions between the m6A and p53 signaling pathways in cancer
Shoemaker, R., Huang, M.-F., Wu, Y., Huang, C., & Lee, D. (2024) · NAR Cancer · doi:10.1093/narcan/zcae037 · Cited by 11
Wang, Z., Yue, S., Chen, X., Li, J., Zhu, P., Chen, H., Qiu, F., Xie, D., Liang, Y., Li, D., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01228 · Cited by 12
Ribosomal proteins in hepatocellular carcinoma: mysterious but promising
Su, Q., Sun, H., Mei, L., Yan, Y., Ji, H., Chang, L., & Wang, L. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01316-3 · Cited by 11
Mitobe, Y., Suzuki, S., Nakagawa-Saito, Y., Togashi, K., Sugai, A., Sonoda, Y., Kitanaka, C., & Okada, M. (2023) · Cancers · doi:10.3390/cancers15174326 · Cited by 9
Wang, L., Lou, Y., & Li, B. (2024) · Journal of Environmental Management · doi:10.1016/j.jenvman.2024.123799 · Cited by 8
Sun, L., Gao, X., Wang, M., Zhang, Y., Sun, R., Chen, Y., Bai, Y., Li, Y., Luo, L., Ding, C., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217854 · Cited by 9
Synthetic approaches to constructing proteolysis targeting chimeras (PROTACs)
Bakulina, O., Sapegin, A., Bunev, A. S., & Krasavin, M. (2022) · Mendeleev Communications · doi:10.1016/j.mencom.2022.07.001 · Cited by 9
Wang, S., Zhao, Y., Yao, F., Wei, P., Ma, L., & Zhang, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116437 · Cited by 9
USP33 Regulates DNA Damage Response and Carcinogenesis Through Deubiquitylating and Stabilising p53
Zhu, Y., Chen, Z., Niu, K., Li, M., Deng, Y., Zhang, J., Wei, D., Wang, J., & Zhao, Y. (2024) · Cell Proliferation · doi:10.1111/cpr.13793 · Cited by 7
Wang, X., Li, Y., Pan, M., Lu, T., Wang, M., Wang, Z., Liu, C., & Hu, G. (2022) · Clinical Science · doi:10.1042/cs20220581 · Cited by 9
Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?
Wang, W., Du, Y., Datta, S., Fowler, J. F., Sang, H. T., Albadari, N. G., Li, W., Foster, J. H., & Zhang, R. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101156 · Cited by 8
How does TCR-T cell therapy exhibit a superior anti-tumor efficacy
Yang, D., Duan, Z., Yuan, P., Ding, C., Dai, X., Chen, G., & Wu, D. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149209 · Cited by 7
Meenakshy, C. B., Sudheendranath, A., Thomas, N. V., Asha, V. S., Biju, P. G., & Deepthi, A. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.137026 · Cited by 7
LRP8 promotes tumorigenesis in ovarian cancer through inhibiting p53 signaling
Xu, Y., Zhou, Y., Yi, X., & Nie, X. (2024) · Cell Biology International · doi:10.1002/cbin.12133 · Cited by 7
Koirala, M., & Fagerquist, C. K. (2025) · Molecules · doi:10.3390/molecules30061277 · Cited by 7
Sanati, M., Afshari, A. R., Ahmadi, S. S., Moallem, S. A., & Sahebkar, A. (2023) · BioFactors · doi:10.1002/biof.1958 · Cited by 7
Waziri, P. M., Auta, R., Imam, M. U., Chindo, B. A., Ladan, Z., Mohammed, Z. T., Wayah, S. B., Mohammed, J., Tahir, M. I., Ahmad, A. E.-F., et al. (2024) · Journal of Evidence-Based Integrative Medicine · doi:10.1177/2515690x241251558 · Cited by 6
Dysregulation of ubiquitination modification in renal cell carcinoma
You, H., Zhang, H., Jin, X., & Yan, Z. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1453191 · Cited by 7
Peptide-driven strategies against lung cancer
Karankar, V. S., Awasthi, S., & Srivastava, N. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123453 · Cited by 7
Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer
Grazia, G., Conti, C., Nucera, S., Stella, S., Massimino, M., Giuliano, M., Schettini, F., Vigneri, P. G., & Martorana, F. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104834 · Cited by 7
Lim, C., Lee, P., Shim, S., & Jang, S. (2022) · Oncology Letters · doi:10.3892/ol.2022.13410 · Cited by 6
High-content morphological profiling by Cell Painting in 3D spheroids
Ringers, C., Holmberg, D., Larsson, A., Jung, B., Jarvius, M., Łuchniak, A., Rosén, D., Johansson, M., Georgiev, P., Seashore-Ludlow, B. A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-78596-5 · Cited by 7
Oljačić, S., Popovic-Nikolic, M., Filipić, B., Gagić, Ž., & Nikolic, K. M. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266337668241025061804 · Cited by 5
Toldo, S., Poletti, L., Carmine, G. D., Bortolini, O., Risi, C. D., Felletti, S., Compagnin, G., Massi, A., & Ragno, D. (2025) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202500058 · Cited by 5
Mechanisms and molecular characterization of relapsed/refractory neuroblastomas
Chen, C., & Wei, Z. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1555419 · Cited by 7
Hot-Spot-Guided Generative Deep Learning for Drug-Like PPI Inhibitor Design
Sun, H., Li, J., Zhang, Y., Lin, S., Chen, J., Tan, H., Wang, R., Mao, X., Zhao, J., Li, R., et al. (2025) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-025-00756-w · Cited by 6
Xue, J., Wang, M., Zhao, Q., Wang, Y., Yang, Q., & Han, B. (2022) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202200846 · Cited by 5
Heat shock factor 1 is a promising therapeutic target against adult T-cell leukemia
Ishikawa, C., & Mori, N. (2023) · Medical Oncology · doi:10.1007/s12032-023-02042-5 · Cited by 5
An updated review of a novel method for examining P53 mutations in different forms of cancer
Shomali, N., Kamrani, A., Nasiri, H., Heris, J. A., Shahabi, P., Yousefi, M., Mohammadinasab, R., Sadeghvand, S., & Akbari, M. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154585 · Cited by 5
miR-660: A novel regulator in human cancer pathogenesis and therapeutic implications
Wang, Z., Su, X., Zhan, Z., Wang, H., Zhou, S., Mao, J., Xu, H., & Duan, S. (2025) · Gene · doi:10.1016/j.gene.2025.149434 · Cited by 5
Cucurbitacin B in cancer: A comprehensive review of its targets and molecular mechanisms
Mi, L., He, T., Lei, D., Lei, D., Su, A., Wei, T., Li, Z., & Wu, W. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117240 · Cited by 6
How to Shut Down Transcription in Archaea during Virus Infection
Pilotto, S., & Werner, F. (2022) · Microorganisms · doi:10.3390/microorganisms10091824 · Cited by 4
Sebák, F., Ecsédi, P., Nyitray, L., & Bodor, A. (2023) · Biomolecular NMR Assignments · doi:10.1007/s12104-023-10160-4 · Cited by 4
Yuan, Y., Zhou, Z., Chen, S., Liu, Y., Li, Y., Miao, Y., Wang, S., Shen, Z., Zeng, L., Xiao, J. Y., et al. (2025) · Reproduction and Breeding · doi:10.1016/j.repbre.2025.02.003 · Cited by 3
Design and Optimization of Spiro-Isatin-Thiazolidinone Hybrids with Promising Anticancer Activity
Khyluk, D., Holota, S. M., Finiuk, N. S., Stoika, R. S., Rumynska, T. M., & Lesyk, R. (2025) · Pharmaceuticals · doi:10.3390/ph18101502 · Cited by 3
Yang, J., & Shen, Y. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11054-5 · Cited by 3
Stetson, S., Mancía, F. C., & Thayer, K. M. (2025) · ACS Omega · doi:10.1021/acsomega.5c05639 · Cited by 3
Research Progress in Function and Regulation of E3 Ubiquitin Ligase SMURF1
Wan, J.-X., Wang, Y., Lan, S.-N., Chen, L., Feng, M., & Chen, X. (2023) · Current Medical Science · doi:10.1007/s11596-023-2774-x · Cited by 3
Wang, C., Chang, R., Li, J., & Li, L. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01308-7 · Cited by 3
MDM2 is essential to maintain the homeostasis of epithelial cells by targeting p53
Wang, S., Zhong, S., Huang, Y., Zhu, S., Chen, S., Wang, R., Wangmo, S., Peng, B., Lv, H., Yang, J., et al. (2024) · Journal of Innate Immunity · doi:10.1159/000539824 · Cited by 3
Unlocking the potential of LHPP: Inhibiting glioma growth and cell cycle via the MDM2/p53 pathway
Guo, L., Chen, W., Yue, J., Gao, M., Zhang, J., Huang, Y., Xiong, H., Li, X., Wang, Y., Yuan, Y., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167509 · Cited by 3
Chakraborty, R., Dutta, A., & Mukhopadhyay, R. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03841-6 · Cited by 5
Gu, M.-Y., Ma, W., Ma, Z.-M., Ma, L., & Ding, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-94504-1 · Cited by 3
Oncogenic Fusions with Aberrant Transcriptional Regulation
You, K., Chen, T., Wang, Y., Li, P., & Li, T. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169268 · Cited by 3
Molecular and Cellular Effects of CT Scans in Human Adipose Mesenchymal Stem Cells
Ignatov, M. A., Markelova, E. E., Chigasova, A., Osipov, A., Buianov, I., Fedotov, Y. А., Eremin, P. S., Vorobyeva, N. Y., Zyuzikov, N., & Osipov, A. N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178584 · Cited by 3
Basha, N. J., & Mohan, R. M. (2024) · ChemistrySelect · doi:10.1002/slct.202304525 · Cited by 4
Zhao, N., You, W., Zheng, X., Yan, J., Wang, P., Yao, Y., He, W., & Liu, T. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102136 · Cited by 4
Expression and Function of FAM72A Gene in Multiple MyelomaFAM72A
Gao, W., & Ma, Y. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010311258240729080309 · Cited by 3
Vaubel, R. A., Zhang, W., Oh, J.-H., Mladek, A. C., Pasa, T. I., Gantchev, J. K., Waller, K. L., Baquer, G., Stopka, S. A., Regan, M. S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0244 · Cited by 2
Lu, C., Li, X., Zhao, X., Zou, Z., Zhao, J., Liu, J., Zhao, Y., & Zou, W. (2025) · All Life · doi:10.1080/26895293.2025.2547248 · Cited by 2
The guardian of the genome meets immunotherapy: p53-based strategies
Savostyanova, T. A., Lopatnikova, J., & Sennikov, S. V. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1762679 · Cited by 3
Designer polyQ fusion proteins sequester USP7/HDM2 for modulating P53 functionality
Zhang, X., Yue, H.-W., Liu, Y., Wang, J., Duan, H.-T., Liu, Y.-H., Jiang, L., & Hu, H. (2025) · iScience · doi:10.1016/j.isci.2025.112025 · Cited by 3
Vargahan, S. E., Barati, M., Roudbari, M., Eini, M., & Hosseini, A. (2024) · Bioimpacts · doi:10.34172/bi.30032 · Cited by 2
Liu, Z., Xia, G., Liang, X., Li, B., & Deng, J. (2024) · Clinical Epigenetics · doi:10.1186/s13148-024-01689-9 · Cited by 2
Zhao, R., Cui, Y., Li, D., Guo, X., Cheng, C., He, R., Hu, C., & Wei, X. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107637 · Cited by 2
Discovery of a Phenylalanine‐Derived Natural Compound as a Potential Dual Inhibitor of MDM2 and MDMX
Cho, J. Y., Park, S., Kim, T., Eom, J., Rho, J., & Bai, H. (2025) · ChemMedChem · doi:10.1002/cmdc.202500397 · Cited by 2
Eid, A. H., Al-Karmalawy, A. A., Abdelhameed, R. F. A., Mostafa, Y. M., Helal, G. K., Mehanna, E. T., & Hazem, R. M. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04196-7 · Cited by 2
Oraibi, A. I., Dawood, A. H., Debbabi, N., Almukram, A. M. A., Almaary, K. S., Dabiellil, F., Ghédira, L. C., & Kilani, S. (2025) · Open Chemistry · doi:10.1515/chem-2025-0142 · Cited by 2
Kalathiya, U., Marek-Trzonkowska, N. M., & Padariya, M. (2026) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2026.105554 · Cited by 2
Nuti, E., Pietra, V. L., Daniele, S., Cuffaro, D., Ciccone, L., Giacomelli, C., Cason, C., Carotenuto, A., D’Amore, V. M., Pozzo, E. D., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15111318 · Cited by 3
Yasin, A., Yasin, A. R., Azam, M. R., Raza, A., Nazir, R., & Abdalla, R. A. E. (2022) · Applied Sciences · doi:10.3390/app12115748 · Cited by 2
Foldamers as Inhibitors of Aberrant Protein–Protein Interactions
Stillman, N. H., Dohoney, R. A., Baysah, C. Z., & Kumar, S. (2025) · Wiley eBooks · doi:10.1002/9783527845828.ch8 · Cited by 2
Metadata
- Authors
- Koo, N., Sharma, A. K., & Narayan, S.
- Affiliations
- University of Florida (US)
- Penn State Cancer Institute (US)
- Corresponding author
- Narayan, Satya
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-04-30
- Volume
- 23
- Issue
- 9
- Pages
- 5005
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9103871
- OpenAlex
- W4225255854
- Cited by
- 153
- References
- 135
- Citations by year
- 2026: 32 · 2025: 46 · 2024: 43 · 2023: 19 · 2022: 13
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Department of Anatomy and Cell Biology, University of Florida
- Department of Pharmacology, Penn State University College of Medicine
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- p53, MDM2, p53-MDM2 interaction, p53 reactivation, MDM2 inhibitors, p53 phosphorylation, tumor suppressor, cancer cell death, apoptosis, cell cycle arrest, cancer therapeutics
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Tumor Suppressor Protein p53, Cell Death, Apoptosis, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.